FDA Approves Sotorasib with Panitumumab for KRAS G12C-mutated Colorectal Cancer By Ogkologos - February 13, 2025 486 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CodeBreaK 300 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Targeting CLDN18.2 with Zolbetuximab Prolongs Survival When Combined with mFOLFOX6 in... April 19, 2023 FDA Approves Elacestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... February 7, 2023 Spirituality Resources December 9, 2020 Dad Creates Inclusive Children’s Book For Daughter With Disability And Others... January 25, 2022 Load more HOT NEWS Enhertu Marks First Targeted Therapy for HER2-Mutant Lung Cancer The Combination of Nivolumab and Cabozantinib Provides a New First-Line Treatment... Double Mastectomies Do Not Lower Risk Of Death For Breast Cancer... Twins Born 15 Minutes Apart Have Birthdays In Different Years
